|
Market Closed -
Nasdaq
04:00:00 2026-07-10 pm EDT
|
5-day change
|
1st Jan Change
|
|
10.89 USD
|
-4.93%
|
 |
+5.83%
|
+77.07%
|
|
Jul. 09 |
Immucell Corporation Reports Preliminary Unaudited Sales Results for the Second Quarter and Six Months Ended June 30, 2026
|
CI
| |
Jul. 09 |
ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
|
AQ
| |
May. 15 |
ImmuCell Corporation, Q1 2026 Earnings Call, May 15, 2026
| | |
May. 14 |
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
|
AQ
| |
May. 14 |
ImmuCell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026
|
CI
| |
May. 08 |
ImmuCell, Norbrook enter settlement deed on May 8, 2026 - SEC filing
|
RE
| |
May. 07 |
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
|
AQ
| |
Apr. 22 |
ImmuCell : Corporate Presentation (Investor Relations April 2026 Final)
|
PU
| |
Apr. 13 |
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
|
AQ
| |
Apr. 13 |
ImmuCell Corporation Announces Board Changes
|
CI
| |
Apr. 08 |
ImmuCell Q1 Sales Jump; Shares Rise After Hours
|
MT
| |
Apr. 08 |
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
|
AQ
| |
Apr. 08 |
Immucell Corporation Announces Preliminary, Unaudited Sales Results for the Firs Quarter of 2026
|
CI
| |
Mar. 18 |
Immucell Corporation Announces Changes to Its Board, Effective April 1, 2026
|
CI
| |
Mar. 18 |
ImmuCell : 03-18-26 – ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
|
PU
| |
Mar. 18 |
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
|
AQ
| |
Mar. 05 |
ImmuCell Corporation, Q4 2025 Earnings Call, Mar 05, 2026
| | |
Mar. 04 |
ImmuCell Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
|
CI
| |
Mar. 04 |
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
|
AQ
| |
Feb. 18 |
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
|
AQ
| |
Feb. 09 |
Steven A. Rosgen and Bryan K. Gathagan Have Decided Not to Seek Re-Election as Directors of ImmuCell Corporation
|
CI
| |
Jan. 09 |
ImmuCell Corporation, Q4 2025 Sales/ Trading Statement Call, Jan 09, 2026
| | |
Jan. 08 |
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
|
AQ
| |
Jan. 08 |
Immucell Corporation Announces Preliminary, Unaudited Sales Results for the Fourth Quarter and Full Year Ended December 31, 2025
|
CI
| |
Jan. 07 |
ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
|
AQ
|
No results match your criteria Select your edition All financial news and data tailored to specific country editions | 
Choose MarketScreener 
